$ZBIO News

Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know

Zenas BioPharma Stock Gains Attention After Long Term Trial Data

Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release

HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

Zenas BioPharma Presents New Obexelimab Data In Immunoglobulin G4-Related Disease At 6th International Symposium On IgG4-Related Disease

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

Zenas BioPharma to Host Virtual R&D Event

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48

Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target

Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript

Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?

Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?

Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026

Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zenas BioPharma Registers Resale Of Up To 7M Shares By Selling Stocholder